Key result
The Modified CHADS2 score demonstrated good and consistent predictive performance for ischaemic stroke across all kidney function strata (c-statistic 0.78 in normal eGFR; 95% CI 0.77-0.79).
Why the study?
The predictive performance of commonly used risk scores for ischaemic stroke in patients with chronic kidney disease and atrial fibrillation was unclear.
How do commonly used risk scores for ischemic stroke perform in patients with atrial fibrillation across different stages of chronic kidney disease?
Cohort (n=36,004)
How do commonly used risk scores for ischemic stroke perform in patients with atrial fibrillation across different stages of chronic kidney disease?
Effect estimate: c-statistic 0.78 (95% CI 0.77-0.79)
The Modified CHADS2 score provides consistent and superior predictive performance for ischemic stroke in atrial fibrillation patients across all stages of kidney function compared to other common risk scores.
Risk scores perform poorly in advanced CKD; leaves open need for CKD-specific IS prediction tools before guiding anticoagulation in AF.
AIMS: The increasing prevalence of ischaemic stroke (IS) can partly be explained by the likewise growing number of patients with chronic kidney disease (CKD). Risk scores have been developed to identify high-risk patients, allowing for personalized anticoagulation therapy. However, predictive performance in CKD is unclear. The aim of this study is to validate six commonly used risk scores for IS in atrial fibrillation (AF) patients across the spectrum of kidney function. METHODS AND RESULTS: Overall, 36 004 subjects with newly diagnosed AF from SCREAM (Stockholm CREAtinine Measurements), a healthcare utilization cohort of Stockholm residents, were included. Predictive performance of the AFI, CHADS2, Modified CHADS2, CHA2DS2-VASc, ATRIA, and GARFIELD-AF risk scores was evaluated across three strata of kidney function: normal kidney function [estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m2], mild CKD (eGFR 30-60 mL/min/1.73 m2), and advanced CKD (eGFR <30 mL/min/1.73 m2). Predictive performance was assessed by discrimination and calibration. During 1.9 years, 3069 (8.5%) patients suffered an IS. Discrimination was dependent on eGFR: the median c-statistic in normal eGFR was 0.75 (range 0.68-0.78), but decreased to 0.68 (0.58-0.73) and 0.68 (0.55-0.74) for mild and advanced CKD, respectively. Calibration was reasonable and largely independent of eGFR. The Modified CHADS2 score showed good performance across kidney function strata, both for discrimination [c-statistic: 0.78 (95% confidence interval 0.77-0.79), 0.73 (0.71-0.74) and 0.74 (0.69-0.79), respectively] and calibration. CONCLUSION: In the most clinically relevant stages of CKD, predictive performance of the majority of risk scores was poor, increasing the risk of misclassification and thus of over- or undertreatment. The Modified CHADS2 score performed good and consistently across all kidney function strata, and should therefore be preferred for risk estimation in AF patients.
No takes yet. Share an insight, caveat, or question.
Jong et al. (2021) conducted a cohort in Atrial fibrillation (n=36,004). Ischaemic stroke risk scores (including Modified CHADS2) was evaluated on Predictive performance (discrimination and calibration) for ischaemic stroke (c-statistic 0.78, 95% CI 0.77-0.79). The Modified CHADS2 score demonstrated good and consistent predictive performance for ischaemic stroke across all kidney function strata (c-statistic 0.78 in normal eGFR; 95% CI 0.77-0.79).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: